PR Newswire·Mar 5, 2026, 2:10 AM ET

BD Advances Iliac Artery Treatment Across the European Union

BD (Becton, Dickinson and Company) obtained CE Marking for the Revello™ Vascular Covered Stent on March 5, 2026.
The device is a next-generation endovascular solution designed to treat atherosclerotic lesions in the common and external iliac arteries.
The stent combines nitinol self-expanding flexibility with radial resistive force tailored for iliac arteries.
Construction features an ultrathin expanded polytetrafluoroethylene covering, compliant ends to reduce trauma risk, and tantalum radiopaque markers for fluoroscopy visibility.
The tri-axial delivery system includes an atraumatic tip, stability sheath, & thumbwheel for controlled deployment.
The platform offers multiple diameters on a lower profile compared to existing European self-expanding iliac artery stents to potentially reduce access site complications.
The device was introduced at the LINC 2026 congress in Germany.
The AGILITY clinical trial is evaluating the stent's performance in PAD patients under the leadership of Dr. Sean Lyden & Dr. Michael Lichtenberg.
The Revello™ Stent is available in CE-mark-accepting countries across Europe.
In the United States, the device remains an investigational device limited to investigational use only.